These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33444413)

  • 1. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.
    Ojeda DS; Gonzalez Lopez Ledesma MM; Pallarés HM; Costa Navarro GS; Sanchez L; Perazzi B; Villordo SM; Alvarez DE; ; Echavarria M; Oguntuyo KY; Stevens CS; Lee B; Carradori J; Caramelo JJ; Yanovsky MJ; Gamarnik AV
    PLoS Pathog; 2021 Jan; 17(1):e1009161. PubMed ID: 33444413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
    Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
    J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
    Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
    Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient Identification of High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method.
    Nguyen KD; Wirz OF; Röltgen K; Pandey S; Tolentino L; Boyd SD; Pham TD
    Arch Pathol Lab Med; 2021 Oct; 145(10):1221-1227. PubMed ID: 34101801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
    Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
    Front Immunol; 2021; 12():724763. PubMed ID: 34489978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
    Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
    mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening".
    Jin DK; Nesbitt DJ; Yang J; Chen H; Horowitz J; Jones M; Vandergaast R; Carey T; Reiter S; Russell SJ; Kyratsous C; Hooper A; Hamilton J; Ferreira M; Deng S; Straus D; Baras A; Hillyer CD; Luchsinger LL
    PLoS One; 2021; 16(4):e0250319. PubMed ID: 33909646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
    Isho B; Abe KT; Zuo M; Jamal AJ; Rathod B; Wang JH; Li Z; Chao G; Rojas OL; Bang YM; Pu A; Christie-Holmes N; Gervais C; Ceccarelli D; Samavarchi-Tehrani P; Guvenc F; Budylowski P; Li A; Paterson A; Yue FY; Marin LM; Caldwell L; Wrana JL; Colwill K; Sicheri F; Mubareka S; Gray-Owen SD; Drews SJ; Siqueira WL; Barrios-Rodiles M; Ostrowski M; Rini JM; Durocher Y; McGeer AJ; Gommerman JL; Gingras AC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
    Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
    Front Immunol; 2021; 12():614436. PubMed ID: 33790892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand.
    Tandhavanant S; Koosakunirand S; Kaewarpai T; Piyaphanee W; Leaungwutiwong P; Luvira V; Chantratita N
    PLoS One; 2021; 16(8):e0255796. PubMed ID: 34375345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
    Guarino C; Larson E; Babasyan S; Rollins A; Joshi LR; Laverack M; Parrilla L; Plocharczyk E; Diel DG; Wagner B
    PLoS One; 2022; 17(1):e0262868. PubMed ID: 35061843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
    Marklund E; Leach S; Nyström K; Lundgren A; Liljeqvist JÅ; Nilsson S; Yilmaz A; Andersson LM; Bemark M; Gisslén M
    Front Immunol; 2021; 12():750448. PubMed ID: 34795668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
    Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
    Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.